Latest KRTX reports update at 2024-02-22: 2023 ∙ 2022 ∙ 2021

Karuna Therapeutics KRTX

$ 329.83 0.0%

Karuna Therapeutics Balance Sheet 2011-2024 | KRTX

Annual Balance Sheet Karuna Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-169 M	-243 M	-199 M	-	-209 M	-85.4 M	9.72 M	-	-	-	-	-	-
Long Term Debt	13.8 M	3.05 M	5.33 M	-	-	-	3.98 M	-	-	-	-	-	-
Long Term Debt Current	2.84 M	2.28 M	2.18 M	844 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	150 K	102 K	3.99 M	-	-	-	-	-	-
Total Current Liabilities	68.1 M	33.9 M	20.2 M	6.85 M	2.96 M	-	-	-	-	-	-	-	-
Total Liabilities	82 M	37.1 M	25.6 M	8.69 M	3.11 M	909 K	15.5 M	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-998 M	-564 M	-288 M	-144 M	-75.5 M	-32.1 M	-14 M	-	-	-	-	-	-
Total Assets	1.34 B	1.16 B	528 M	348 M	393 M	92.5 M	2.13 M	-	-	-	-	-	-
Cash and Cash Equivalents	186 M	248 M	207 M	53 M	209 M	-	-	-	-	-	-	-	-
Book Value	1.25 B	1.13 B	502 M	339 M	390 M	91.6 M	-13.4 M	-	-	-	-	-	-
Total Shareholders Equity	1.25 B	1.13 B	502 M	339 M	390 M	-29.9 M	-13.4 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Karuna Therapeutics

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	13.8 M	13.8 M	2.69 M	3.05 M	3.61 M	4.18 M	4.76 M	5.33 M	5.89 M	6.44 M	1.62 M	1.84 M	1.84 M	1.84 M	1.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	62.8 M	52.5 M	28 M	37.1 M	44.5 M	28.1 M	20.8 M	25.6 M	21.8 M	16.8 M	8.35 M	8.69 M	8.69 M	8.69 M	8.69 M	3.11 M	3.11 M	3.11 M	3.11 M	3.81 M	3.81 M	3.81 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-884 M	-765 M	-662 M	-564 M	-488 M	-411 M	-346 M	-288 M	-260 M	-209 M	-175 M	-144 M	-144 M	-144 M	-144 M	-75.5 M	-75.5 M	-75.5 M	-75.5 M	-31.6 M	-31.6 M	-31.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	1.39 B	1.47 B	1.52 B	1.16 B	1.23 B	434 M	474 M	528 M	540 M	577 M	593 M	348 M	348 M	348 M	348 M	393 M	393 M	393 M	393 M	15.9 M	15.9 M	15.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	184 M	264 M	563 M	248 M	628 M	136 M	176 M	207 M	252 M	346 M	354 M	53 M	53 M	53 M	53 M	209 M	209 M	209 M	209 M	8.9 M	8.9 M	8.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	1.32 B	1.42 B	1.49 B	1.13 B	1.18 B	405 M	454 M	502 M	518 M	560 M	585 M	339 M	339 M	339 M	339 M	390 M	390 M	390 M	390 M	12 M	12 M	12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	1.32 B	1.42 B	1.49 B	1.13 B	1.18 B	405 M	454 M	502 M	518 M	560 M	585 M	339 M	339 M	339 M	339 M	390 M	390 M	390 M	390 M	-29.9 M	-29.9 M	-29.9 M	-15.7 M	-13.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency